Yates WB - Search Results

1

Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.

Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D. Yates WB, et al. Ophthalmology. 2015 Feb;122(2):265-73. doi: 10.1016/j.ophtha.2014.08.024. Epub 2014 Oct 11. Ophthalmology. 2015. PMID: 25312044

2

Etiology and Clinical Features of Ocular Inflammatory Diseases in a Tertiary Referral Centre in Sydney, Australia.

Zagora SL, Symes R, Yeung A, Yates W, Wakefield D, McCluskey PJ. Zagora SL, et al. Ocul Immunol Inflamm. 2017;25(sup1):S107-S114. doi: 10.1080/09273948.2016.1247871. Epub 2016 Nov 30. Ocul Immunol Inflamm. 2017. PMID: 27901620

3

Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?

Yates WB, McCluskey PJ, Wakefield D. Yates WB, et al. J Ophthalmic Inflamm Infect. 2013 May 31;3(1):48. doi: 10.1186/1869-5760-3-48. J Ophthalmic Inflamm Infect. 2013. PMID: 23724805 Free PMC article.

4

Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.

Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Lee JT, et al. Among authors: yates wb. Br J Ophthalmol. 2018 Dec;102(12):1672-1678. doi: 10.1136/bjophthalmol-2017-311234. Epub 2018 Feb 19. Br J Ophthalmol. 2018. PMID: 29459430

5

Ocular Toxoplasmosis in a Tertiary Referral Center in Sydney Australia-Clinical Features, Treatment, and Prognosis.

Yates WB, Chiong F, Zagora S, Post JJ, Wakefield D, McCluskey P. Yates WB, et al. Asia Pac J Ophthalmol (Phila). 2019 Jul-Aug;8(4):280-284. doi: 10.1097/APO.0000000000000244. Asia Pac J Ophthalmol (Phila). 2019. PMID: 31369405 Free PMC article.

6

Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora.

Ong AP, Angbue Te N, Zagora SL, Symes RJ, Yates W, Chang AA, McCluskey PJ, Simunovic MP. Ong AP, et al. Clin Exp Ophthalmol. 2019 Jan;47(1):57-62. doi: 10.1111/ceo.13345. Epub 2018 Jul 16. Clin Exp Ophthalmol. 2019. PMID: 29931722

7

Is There a Safe Systemic Corticosteroid Dose?

Wakefield D, Yates W, McCluskey P. Wakefield D, et al. Ocul Immunol Inflamm. 2022 Feb 17;30(2):479-480. doi: 10.1080/09273948.2022.2027467. Epub 2022 Jan 20. Ocul Immunol Inflamm. 2022. PMID: 35050828 No abstract available.

8

HLA-B27 Anterior Uveitis: Immunology and Immunopathology.

Wakefield D, Yates W, Amjadi S, McCluskey P. Wakefield D, et al. Ocul Immunol Inflamm. 2016 Aug;24(4):450-9. doi: 10.3109/09273948.2016.1158283. Epub 2016 May 31. Ocul Immunol Inflamm. 2016. PMID: 27245590 Review.

9

Neuro-ophthalmological manifestations of sarcoidosis.

Yates WB, McCluskey PJ, Fraser CL. Yates WB, et al. J Neuroimmunol. 2022 Jun 15;367:577851. doi: 10.1016/j.jneuroim.2022.577851. Epub 2022 Mar 26. J Neuroimmunol. 2022. PMID: 35405430

10

Impact on patient management of non-mydriatic fundus photography compared to direct ophthalmoscopy in a regional Australian emergency department.

Dunn HP, Browning SD, Thomson D, Yates WB, McCluskey P, Keay L, White AJ, Fraser CL. Dunn HP, et al. Among authors: yates wb. Emerg Med Australas. 2022 Apr;34(2):186-193. doi: 10.1111/1742-6723.13845. Epub 2021 Aug 27. Emerg Med Australas. 2022. PMID: 34448357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page